301. Macular dystrophy Clinical trials / Disease details


Clinical trials : 45 Drugs : 46 - (DrugBank : 12) / Drug target genes : 9 - Drug target pathways : 67

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-004783-35-DE
(EUCTR)
10/07/201823/01/2018A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt DiseaseA Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease Autosomal Recessive Stargardt Disease
MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Zimura
Product Code: ARC1905
INN or Proposed INN: avacincaptad pegol
Other descriptive name: ARC1905 20 MG/ML
IVERIC bioNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 2United States;France;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy
2EUCTR2017-004783-35-IT
(EUCTR)
05/06/201825/01/2021A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt DiseaseA Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease - A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subj Autosomal Recessive Stargardt Disease
MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Zimura
Product Code: [ARC1905]
INN or Proposed INN: avacincaptad pegol
Other descriptive name: ARC1905
IVERIC bio, Inc.NULLNot RecruitingFemale: yes
Male: yes
120Phase 2France;United States;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy
3EUCTR2017-004783-35-GB
(EUCTR)
29/05/201826/01/2018A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt DiseaseA Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease Autosomal Recessive Stargardt Disease
MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Zimura
Product Code: ARC1905
INN or Proposed INN: avacincaptad pegol
Other descriptive name: ARC1905 20 MG/ML
IVERIC bioNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 2United States;France;Hungary;Canada;Spain;Israel;Germany;Italy;United Kingdom
4EUCTR2017-004783-35-ES
(EUCTR)
09/04/201802/02/2018A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt DiseaseA Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease Autosomal Recessive Stargardt Disease
MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Zimura
Product Code: ARC1905
INN or Proposed INN: avacincaptad pegol
Other descriptive name: ARC1905 20 MG/ML
OPHTHOTECH CORPORATIONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 2France;United States;Hungary;Canada;Spain;Israel;Germany;Italy;United Kingdom
5EUCTR2017-004783-35-HU
(EUCTR)
21/03/201801/02/2018A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt DiseaseA Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease Autosomal Recessive Stargardt Disease
MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Zimura
Product Code: ARC1905
INN or Proposed INN: avacincaptad pegol
Other descriptive name: ARC1905 20 MG/ML
IVERIC bioNULLNot RecruitingFemale: yes
Male: yes
70Phase 2United States;France;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy